EREADIAN

Innovation versus Financialization in the US Pharmaceutical Industry

Паперова, 2025, 96 с. Cambridge University Press
Big Pharma claims fair prices stifle innovation. Reality: profits fuel shareholders, not breakthroughs. Time for drug price regulation. Mandated by the Inflation Reduction Act of 2022, the US government is negotiating with pharmaceutical companies over the 'maximum fair price' of ten drugs widely used by Medicare patients. The pharmaceutical companies contend that a 'fair' price is a 'value-based price' that enables their shareholders to capture the value the drug creates for society and warn that lowering drug prices will reduce investments in new drugs. This Element responds to these arguments by showing that pharmaceutical companies (a) should have their drug prices regulated, given scale economies in supplying drugs and price inelasticity of drug demand; (b) use their profits from unregulated drug prices to distribute cash dividends and stock buybacks to shareholders; (c) do not typically rely upon investment by shareholders to fund drug innovation; and (d) benefit from 'collective and cumulative learning' in foundational and translational research that is antecedent and external to their investments in clinical research.

Деталі

Видання
Cambridge University Press, 2025, м’яка палітурка
Видавництво
Cambridge University Press
Сторінок
96
Мова
Англійська
ISBN
9781009707985

Ціни

Паперова, 1 пропозиція
В наявності в 1 магазині
Yakaboo
1 483 ₴

Відгуки

Innovation versus Financialization in the US Pharmaceutical Industry

Ще ніхто не оцінив.

Паперова, 2025, 96 с. Cambridge University Press

Про книжку

Big Pharma claims fair prices stifle innovation. Reality: profits fuel shareholders, not breakthroughs. Time for drug price regulation.

Mandated by the Inflation Reduction Act of 2022, the US government is negotiating with pharmaceutical companies over the 'maximum fair price' of ten drugs widely used by Medicare patients. The pharmaceutical companies contend that a 'fair' price is a 'value-based price' that enables their shareholders to capture the value the drug creates for society and warn that lowering drug prices will reduce investments in new drugs. This Element responds to these arguments by showing that pharmaceutical companies (a) should have their drug prices regulated, given scale economies in supplying drugs and price inelasticity of drug demand; (b) use their profits from unregulated drug prices to distribute cash dividends and stock buybacks to shareholders; (c) do not typically rely upon investment by shareholders to fund drug innovation; and (d) benefit from 'collective and cumulative learning' in foundational and translational research that is antecedent and external to their investments in clinical research.

Деталі

Видання
Cambridge University Press, 2025, паперова
Видавництво
Cambridge University Press
Сторінок
96
Мова
Англійська
ISBN
9781009707985

Відгуки

Відгуків ще немає.

Ціни 1 пропозиція

ВиданняCambridge University Press, 2025
Yakaboo
В наявності
1 483 ₴

Деякі посилання на магазини — партнерські, ми можемо отримати невеликий відсоток від магазину, але це не впливає на порядок пропозицій на сайті.

Помітили неправильну ціну?